Polo-like Kinase (PLK)
Polo-like Kinases (PLKs) are a group of highly conserved serine/threonine protein kinases that play a key role in processes such as cell division and checkpoint regulation of mitosis. In mammals, five PLKs (PLK 1-5) encompass diverse roles in centrosome dynamics, spindle formation, intra S-phase and G2/M checkpoints, and DNA damage response.
PLKs are characterized by their Polo-box domain, which mediates protein interactions. They are additionally controlled by phosphorylation, proteolysis, and transcription, depending on the biological context. PLKs are now recognized to link cell division to developmental processes and to function in differentiated cells.
Polo-like Kinase (PLK) Isoform Specific Products
All Product Categories
-
Polo-like Kinase (PLK) Related Products (140)
Related Products (140)
-
Recombinant Proteins (6)
-
Antibodies (3)
-
Polo-like Kinase (PLK) Isoform Comparison
-
PLK4-IN-3
0 ImagesCat. No.: HY-134775ACAS No.: 1247001-86-0
-
PLK1-IN-5
0 ImagesCat. No.: HY-148974CAS No.: 1001343-34-5PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. PLK1-IN-5 shows anticancer effects (WO2008113711A1; compound I-4).
-
PLK1-IN-4
0 ImagesCat. No.: HY-146792CAS No.: 2622273-55-4PLK1-IN-4 is a potent and selective PLK1 inhibitor with IC50 < 0.508 nM. PLK1-IN-4 has broad antiproliferative activity against a variety of cancer cell lines. PLK1-IN-4 induces mitotic arrest at the G2/M phase checkpoint, leading to cancer cell apoptosis. PLK1-IN-4 can be used for researching hepatocellular carcinoma.
-
PLK1-IN-2
0 ImagesCat. No.: HY-139652CAS No.: 2640254-52-8PLK1-IN-2 is a PLK1 kinase inhibitor with an IC50 value of 0.384 μM.
-
PLK1-IN-12
0 ImagesCat. No.: HY-172364PLK1-IN-12 is a highly selective and orally active PLK1 inhibitor with an IC50 of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC50: >10000 nM) and PLK3 (IC50: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research.
-
Anticancer agent 306
0 ImagesCat. No.: HY-181769CAS No.: 3043892-01-6Anticancer agent 306 is a spiro tetramic acid derivative and a inhibitor of MMP1, MMP7 and PLK1. Anticancer agent 306 exerts antiproliferative activity against H1299, RKO and MCF-7 cells with IC50 values of 19.25 μM, 3.29 μM and 102.36 μM, respectively. Anticancer agent 306 can up-regulate p21 protein and down-regulate CCND1 and CCNB1 proteins to induce cell cycle arrest, regulate the expression of Bcl-2 and Bax to induce cell apoptosis. Anticancer agent 306 can down-regulate MMP1 and MMP7 proteins to inhibit tumor invasion and metastasis. Anticancer agent 306 can be used for the research of lung cancer, colorectal cancer, breast cancer.
-
3,4,3'-Tri-O-methylflavellagic acid
0 ImagesCat. No.: HY-N13795CAS No.: 13756-49-53,4,3'-Tri-O-methylflavellagic acid is a flavonoid inhibitor that targets αβ-tubulin (colchicine binding site) and polo-like kinase-1 (PLK-1), and can be isolated from the roots of Anogeissus leiocarpus. 3,4,3'-Tri-O-methylflavellagic acid interferes with microtubule assembly dynamics and kinase activity, exhibiting anti-cancer cell proliferation and potent anti-nociceptive effects.
-
PLK1-IN-10
0 ImagesCat. No.: HY-161521CAS No.: 2991469-21-5PLK1-IN-10 (Compound 4Bb) is an orally active PLK1 PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death.
-
TAK-960 monohydrochloride
0 ImagesCat. No.: HY-15160CCAS No.: 2108449-45-0TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.
-
ZK-Thiazolidinone
0 ImagesCat. No.: HY-104023CAS No.: 891849-87-9ZK-Thiazolidinone is an ATP-competitive Polo-like kinase 1 (Plk1) inhibitor with an IC50 of 19 nM. ZK-Thiazolidinone inhibits tumor cell proliferation, induces cell cycle arrest and typical mitotic defects. ZK-Thiazolidinone impairs the recruitment of γ-tubulin and Aurora A kinase to centrosomes, resulting in failure of bipolar spindle maintenance and sister chromatid arm cohesion.\nZK-Thiazolidinone is applicable for cancer research.
-
PLK1-IN-8
0 ImagesCat. No.: HY-161046PLK1-IN-8 (compound TE6) is a PLK1 inhibitor, and inhibits cell proliferation by blocking the cell cycle at G2 phase. PLK1-IN-8 shows anticancer activity in vivo.
-
PLK2-IN-1
0 ImagesCat. No.: HY-189637PLK2-IN-1 is a selective PLK2 inhibitor (IC50 0.78 μM). PLK2-IN-1 induces Apoptosis and cell cycle arrest, reduces AKT and mTOR phosphorylation, and decreases Cyclin E expression as well as downregulates the CDK2/Rb/E2F1 axis. PLK2-IN-1 inhibits tumor growth in colorectal cancer xenograft models. PLK2-IN-1 can be used for research on colorectal cancer.
-
PLK4-IN-5
0 ImagesCat. No.: HY-179103PLK4-IN-5 (compound 5f) is a PLK4 (IC50 = 0.8 nM) inhibitor. PLK4-IN-5 can inhibit MCF-7 cell clone formation, induce cell cycle arrest (S/G2 phase), and apoptosis. PLK4-IN-5 has anti proliferative activity against MCF-7 cells (IC50 = 0.48 μM). PLK4-IN-5 can be used in the research of cancer such as breast cancer.
-
(S)-BI 2536
0 ImagesCat. No.: HY-50698ACAS No.: 1241725-90-5(S)-BI 2536 is the enantiomer of BI 2536 (HY-50698). (S)-BI 2536 acts as an inhibitor of the BRD4 bromodomain and PLK1 kinase, with a Ki value of 54 nM against BRD4 and a Ki value of 0.42 nM against PLK1 kinase. (S)-BI 2536 exhibits anticancer activity against acute myeloid leukemia. (S)-BI 2536 can be used for the research of acute myeloid leukemia.
-
PLK1-IN-7
0 ImagesCat. No.: HY-156336CAS No.: 2938910-96-2PLK1-IN-7 (compound 30e) is a potent PLK1 inhibitor, with an IC50 of 0.66 nM. PLK1-IN-7 exhibits antiproliferative and antitumor activities.
